Diego Adrianzen Herrera, M.D., M.S.

BIO

Dr. Diego Adrianzen Herrera is a medical oncologist at the University of Vermont Cancer Center specializing in malignant hematology (blood cancers) including leukemia, lymphoma and multiple myeloma. He has a special focus in acute leukemias and myelodysplastic neoplasms. He also serves as an assistant professor at the University of Vermont Larner College of Medicine. In a clinical setting, Dr. Adrianzen Herrera seeks to understand not just the medical needs of his patients, but also their right to clarity, honesty, and dignity. He focuses on providing patient-centered care, empowering his patients by involving them in treatment decisions and educating them about their condition. While not caring for his patients, he is conducting clinical research centered around cardiovascular outcomes and health disparities in patients with blood cancers, inflammation biomarkers in myeloid cancers, and therapeutic clinical trials for patients with acute leukemia.

Dr. Adrianzen Herrera's postdoctoral training

2019   Hematology & Medical Oncology Fellowship, Albert Einstein College of Medicine, New York 
2016   Internal Medicine Residency, Ichan School of Medicine at Mount Sinai, New York

Publications

Dr. Adrianzen Herrera's Bibliography

Awards and Achievements

• 2020 Young Investigator Award – Cardiovascular Research Institute of Vermont
• 2020 Collaborative Research Grant - Northern New England Clinical Oncology Society
• 2021 Green and Gold Early Career Professorship - University of Vermont
• 2021-2022 Clinical Research Training Institute Scholar - American Society of Hematology
• 2022-2024 Mentored Research Award - Hemostasis and Thrombosis Research Society
• 2022 Research Grant – University of Vermont Health Network Medical Group
• 2024 Pilot Award - American Cancer Society/University of Vermont Cancer Center 

Area(s) of expertise

Dr. Adrianzen Herrera's research focuses on health outcomes and translational epidemiology on hematologic cancer. He has used population databases to study cardiovascular health among patients with myelodysplastic neoplasms and determine the sociodemographic factors which affect their long-term outcomes. He is also exploring proteomics to identify inflammatory biomarkers of disease in this population. 

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes (Neoplasms)
• Myeloproliferative Neoplasms
• Clonal hematopoiesis and leukemogenesis
• Proteomics in hematologic malignancies
• Health disparities in blood cancer treatment
   

Selected publications: 

Batra A, Sparks A, Singh R, Zakai NA, Adrianzen Herrera D. Characteristics and survival of secondary acute myeloid leukemia from myelodysplastic syndromes in older adults: A population analysis. Clin Lymphoma Myeloma Leuk 2025, Jan 23 [Epub ahead of print]. PMID 39952850 

Adrianzen Herrera D, Strumlowska A. Role of population based studies in advancing our knowledge of myelodysplastic syndromes. Curr Hematol Malig Rep 2025, Jan 17;20(1):6. PMID 39821758 

Adrianzen Herrera D, Sparks AD, Singh R, Alejos-Castillo D, Batra A, Glushakow-Smith S, Pradhan K, Shastri A, Zakai NA. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis. Blood Adv 2023, Nov 28;7(22):6913-6922. PMID 37729616. 

Adrianzen Herrera D, Sparks AD, Batra A, Zakai NA. Survival gains in Myelodysplastic Syndromes following a decade of the modern treatment paradigm. Leuk Lymphoma 2023, Sep;64(9):1574-1578. PMID 37300451. 

Bazarbachi AH, Reef D, Narvel H, Patel R, Al Hamed R, Vikash S, Neupane K, Atalla E, Thakkar A, Rahman S, Shah U, Adrianzen Herrera D, Quinn R, Zareef S, Rabinovich E, De Castro A, Joseph F, Gillick K, Mustafa J, Khatun F, Lombardo A, Townsend-Nugent L, Abreu M, Chambers N, Elkind R, Shi Y, Wang Y, Derman O, Gristman K, Steidl U, Goldfinger M, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Shah N, Cooper D, Verma A, Ye BH, Janakiram M, Sica RA. Outcome of stem cell transplantation in HTLV-1-associated North American Adult T-Cell Leukemia/Lymphoma. Clin Hematol Int 2023, Jun;5(2-3):78-91. PMID 36918485. 

Adrianzen Herrera D, Lutsey P, Giorgio K, Walker R, Zakai N. Bleeding risk in patients with Multiple Myeloma treated for Venous Thromboembolism: a MarketScan analysis. Res Pract Thromb Haemost 2022, Dec 23;7(1):1000024. PMID: 36873562. 

Adrianzen Herrera D, Koh I, Gangaraju R, Akinyemiju T, Zakai N. Association between Peripheral Blood Cytopenia and Cancer Mortality: A race-specific risk factor for cancer death. Cancer Med 2022, Dec 30;10.1002/cam4.5570. PMID: 36583503. 

Adrianzen Herrera D, Sparks AD, Shastri A, Zakai NA, Littenberg B. Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis. Cancer Epidemiol 2022, Oct;80:102238. PMID 35970010.  

Adrianzen Herrera D, Shastri A. Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road. Clin Cancer Res 2022, Oct 3;28(19):4167-4170. PMID: 35876635. 

Shastri A, Adrianzen Herrera D. Ruxolitinib in CMML: A case-study of innovative trial design in rare cancers. Clin Cancer Res 2021, Nov 15; 27(22):6069-6071. PMID: 34531297. 

Ades S, Adrianzen Herrera D, Lahey T, Thomas AA, Jasra S, Barry M, Sprague J, Dittus, Plante TB, Kelly J, Kaufman PA, Khan F, Hammond CJ, Gernander K, Parsons P, Holmes C. Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect. JCO Oncol Pract 2021, Aug 2; OP100116. PMID: 34339260. 

Adrianzen Herrera D, Choudhary G, Gordon-Mitchell S, Ramachandra N, Bhagat T, Zhang H, Aluri S, Yang WL, Shastri A, Steidl U, Will B, Mahler M, Eichembaum G, Guha C, Verma A. The novel thrombopoietin mimetic JNJ-23366821 increases megakaryopoiesis without affecting malignant myeloid proliferation. Leuk Lymphoma 2020, Oct; 61(10):2453-2465. PMID 32578476. 

Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Braunschweig I, Budhathoki A, Verma A, Murthy S, Shastri A. Myelodysplastic Syndromes and the Risk of Cardiovascular Disease in Older Adults: A SEER-Medicare Analysis. Leukemia 2020, Jun;34(6):1689-1693. PMID 31844145.  

Dr. Adrianzen Herrera's publications on Google Scholar

Dr. Adrianzen Herrera's publications on PubMed